Ravulizumab Cut Proteinuria by 43% in Phase 3 IgA Nephropathy Interim
Start here
An interim analysis of a phase 3 trial tested ravulizumab, a complement inhibitor, in IgA nephropathy, a disease in which antibody deposits damage the kidneys' filtering units and drive protein loss in urine. Of 485 randomized patients, 352 were included in the analysis. At week 34, ravulizumab produced a 24-hour urinary protein-to-creatinine ratio 43.4% lower than placebo. With ravulizumab, the geometric mean ratio fell 46.6%, from 1.56 to 0.83, while placebo produced only a 5.6% decline, from 1.60 to 1.48. The interim results, published in the New England Journal of Medicine on October 24, 2026, indicate a substantial reduction in proteinuria. Full trial completion and longer-term kidney outcomes remain open questions.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- N Engl J MedPickRavulizumab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
In an interim analysis of a phase 3 trial in IgA nephropathy, ravulizumab produced a 24-hour urinary protein-to-creatinine ratio at week 34 that was 43.4% lower than placebo. Of 485 randomized patients, 352 were included in the interim analysis; the geometric mean ratio fell from a baseline of 1.56 to 0.83 with ravulizumab, a 46.6% reduction, versus 1.60 to 1.48 with placebo, a 5.6% reduction.
Heat trend for this story
Heat now 11·Peak in the comparable set 16 (Oct 24 01:00)·Change over 24h in the comparable set +37%·Participants now 2
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.